Healthcare -
Medical - Devices - NASDAQ - CA
$ 5.975
-1.89 %
$ 180 M
Market Cap
-4.94
P/E
1. INTRINSIC VALUE
Balance Sheet
Profound Medical Corp.
| Current Assets | 69.1 M |
| Cash & Short-Term Investments | 54.9 M |
| Receivables | 7.04 M |
| Other Current Assets | 7.11 M |
| Non-Current Assets | 1.17 M |
| Long-Term Investments | 0 |
| PP&E | 489 K |
| Other Non-Current Assets | 680 K |
| Current Liabilities | 6.56 M |
| Accounts Payable | 1.32 M |
| Short-Term Debt | 1.99 M |
| Other Current Liabilities | 3.25 M |
| Non-Current Liabilities | 3.25 M |
| Long-Term Debt | 3.13 M |
| Other Non-Current Liabilities | 122 K |
EFFICIENCY
Earnings Waterfall
Profound Medical Corp.
| Revenue | 10.7 M |
| Cost Of Revenue | 3.64 M |
| Gross Profit | 7.04 M |
| Operating Expenses | 40.1 M |
| Operating Income | -33.1 M |
| Other Expenses | -5.25 M |
| Net Income | -27.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Profound Medical Corp.
| Net Income | -27.8 M |
| Depreciation & Amortization | 891 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 2.58 M |
| Change in Working Capital | 591 K |
| Others | -735 K |
| Free Cash Flow | -23.5 M |
Wall Street Analysts Price Targets
Profound Medical Corp.
Wall Street analysts predict an average 1-year price target for PROF of $15.8 , with forecasts ranging from
a
low of
$12 to a high of $17 .
PROF Lowest Price Target
Wall Street Target
12 USD
100.84%
PROF Average Price Target
Wall Street Target
15.8 USD
164.44%
PROF Highest Price Target
Wall Street Target
17 USD
184.52%
4. DIVIDEND
ANALYSIS
PROF does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Profound Medical Corp.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
100 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Profound Medical (NASDAQ:PROF) Shares Up 17.4% – What’s Next?
Profound Medical Corp. (NASDAQ:PROF – Get Free Report) shares shot up 17.4% during mid-day trading on Tuesday . The stock traded as high as $6.90 and last traded at $6.75. 139,248 shares traded hands during trading, an increase of 117% from the average session volume of 64,191 shares. The stock had previously closed at $5.75. Analyst Upgrades and Downgrades Several brokerages have recently issued reports on PROF. Raymond James cut shares of Profound Medical from a “strong-buy” rating to a “moderate buy” rating in a research report on Friday, May 9th. Lake Street Capital reduced their price target on shares of Profound Medical from $17.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, April 23rd. Read Our Latest Stock Analysis on PROF Profound Medical Price Performance The firm has a market cap of $202.86 million, a price-to-earnings ratio of -5.04 and a beta of 0.48. The company has a quick ratio of 5.16, a current ratio of 6.12 and a debt-to-equity ratio of 0.11. The company’s 50-day moving average price is $4.95 and its 200-day moving average price is $6.33. Profound Medical (NASDAQ:PROF – Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $2.62 million during the quarter, compared to analyst estimates of $4.78 million. Profound Medical had a negative net margin of 349.41% and a negative return on equity of 85.22%. On average, equities research analysts forecast that Profound Medical Corp. will post -1.12 EPS for the current year. Insider Activity at Profound Medical In other news, CEO Arun Swarup Menawat bought 10,003 shares of Profound Medical stock in a transaction that occurred on Thursday, May 15th. The shares were purchased at an average price of $4.33 per share, with a total value of $43,312.99. Following the completion of the acquisition, the chief executive officer now directly owns 575,062 shares in the company, valued at $2,490,018.46. The trade was a 1.77% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.52% of the stock is owned by corporate insiders. Hedge Funds Weigh In On Profound Medical Several hedge funds have recently added to or reduced their stakes in PROF. PNC Financial Services Group Inc. purchased a new position in Profound Medical in the first quarter valued at approximately $64,000. XTX Topco Ltd purchased a new position in Profound Medical in the fourth quarter valued at approximately $114,000. MTM Investment Management LLC increased its stake in Profound Medical by 10.4% in the fourth quarter. MTM Investment Management LLC now owns 18,575 shares of the company’s stock valued at $139,000 after purchasing an additional 1,750 shares during the last quarter. Marshall Wace LLP increased its stake in Profound Medical by 201.6% in the fourth quarter. Marshall Wace LLP now owns 36,216 shares of the company’s stock valued at $272,000 after purchasing an additional 24,208 shares during the last quarter. Finally, Northwest & Ethical Investments L.P. increased its stake in Profound Medical by 94.9% in the fourth quarter. Northwest & Ethical Investments L.P. now owns 46,200 shares of the company’s stock valued at $346,000 after purchasing an additional 22,500 shares during the last quarter. 47.86% of the stock is currently owned by hedge funds and other institutional investors. Profound Medical Company Profile (Get Free Report) Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. See Also Five stocks we like better than Profound Medical How to trade using analyst ratings AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway How to Use the MarketBeat Dividend Calculator Casey’s Surges on Strong Q4, More Gains Likely Ahead Retail Stocks Investing, Explained Government Mandate Sends eVTOL Stocks Flying
https://www.defenseworld.net
- 1 month ago
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting.
globenewswire.com
- 2 months ago
Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript
Profound Medical Corporation (NASDAQ:PROF ) Q1 2025 - Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Stephen Kilmer - Head IR Rashed Dewan - CFO Dr. Mathieu Burtnyk - COO Tom Tamberrino - Chief Commercial Officer Arun Menawat - CEO Conference Call Participants Ben Haynor - Lake Street Capital Markets John McAuley - Stifel Michael Freeman - Raymond James Scott McAuley - Paradigm Capital Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter 2025 Financial Results Conference Call.
seekingalpha.com
- 2 months ago
Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.26 per share a year ago.
zacks.com
- 2 months ago
Strength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
zacks.com
- 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK CITY, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accessnewswire.com
- 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accessnewswire.com
- 2 months ago
Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025 at 1:30 p.m. Eastern Time at the Metro Toronto Convention Centre.
globenewswire.com
- 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accessnewswire.com
- 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
globenewswire.com
- 2 months ago
Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy
– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – TORONTO, April 29, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce initial perioperative data from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA procedure with radical prostatectomy (“RP”) in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. The positive perioperative results were presented yesterday by Xiaosong Meng, M.D.
globenewswire.com
- 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK , April 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
prnewswire.com
- 2 months ago
8. Profile
Summary
Profound Medical Corp. PROF
COUNTRY
CA
INDUSTRY
Medical - Devices
MARKET CAP
$ 180 M
Dividend Yield
0.00%
Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Contact
2400 Skymark Avenue, Mississauga, ON, L4W 5K5
https://www.profoundmedical.com
IPO
Date
Oct. 29, 2019
Employees
142
Officers
Mr. Levant Tinaz
Software Developer
Dr. Arun Swarup Menawat MBA, Ph.D.
Chairman of the Board & Chief Executive Officer
Mr. Stephen Kilmer
Investor Relations
Dr. Mathieu Burtnyk Ph.D.
President
Mr. Rashed Dewan
Chief Financial Officer
Mr. Matthew Sobczyk C.A., CPA
Assistant Corporate Controller
Mr. Thomas Tamberrino MBA
Chief Commercial Officer